Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01447914 · ClinicalTrials.gov registry record · Phase 2
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01447914: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01447914 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01447914, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well tivantinib works in treating patients with relapsed, or relapsed and refractory multiple myeloma. Tivantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Questionnaire administration
- PROCEDURE Quality-of-life assessment
- DRUG Tivantinib
- OTHER Diagnostic laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01447914
The ClinicalTrials.gov registry entry for NCT01447914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Questionnaire administration is the first listed.
NCT01447914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01447914 about?
NCT01447914 is a clinical study titled "Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma". This phase II trial studies the side effects and how well tivantinib works in treating patients with relapsed, or relapsed and refractory multiple myeloma. Tivantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01447914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01447914?
The interventions under investigation include: Questionnaire administration (OTHER), Quality-of-life assessment (PROCEDURE), Tivantinib (DRUG), Diagnostic laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT01447914?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.